Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Consumer Business Picks Up, But Analysts See Long Road

This article was originally published in The Tan Sheet

Executive Summary

The consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.

Advertisement

Related Content

China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid Responses
China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid Responses
Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s
J&J’s Gorsky Promises Prioritization Of OTC Business
McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel